Shots: Shots:

• Boehringer Ingelheim acquires two preclinical programs from Northern Biologic to foster its cancer immunology portfolio in exchange Northern will receive upfront- milestones and other consideration payments. The acquisition will support Boehringer’s strategy to target ‘’cold tumors with synergistic combination approaches”
• The first program is an Ab inhibitor of Periostin- which contributes to cancer cell growth while the second program targets a key regulator of myeloid cells which plays a role in enhancing the anti-tumor T-cell function
• The seller will retain the Northern’s name and will continue to drive certain preclinical efforts on one of the programs while Boehringer will be responsible for clinical- regulatory and commercial development of the acquired programs.  Northern will retain rights to its lead asset- MSC-1- that completed it P-I clinical studies

Click here ­to­ read full press release/ article | Ref: Boehringer Ingelheim  | Image: Square space

Related News: Boehringer Ingelheim Acquires AMAL Therapeutics for its KISIMA Immunization Platform